1. |
Rebecca LS, Kimberly DM, Ahmedin J. Cancer statistics, 2016. CA: Cancer J Clin, 2016, 66(1): 7-30.
|
2. |
尹光浩, 刘伟, 刘国津, 等. 非小细胞肺癌的 EGFR 表达与 EGFR 基因突变的比较. 中国实验诊断学, 2009, 13(2): 200-202.
|
3. |
Bronte G, Rolfo C, Giovannetti E, et al. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Crit Rev Oncol Hematol, 2014, 89(2): 300-313.
|
4. |
Travis WD, Brambilla E, Noguchi MT, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc, 2011, 8(5): 381-385.
|
5. |
Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol, 2015, 10(9): 1243-1260.
|
6. |
Hirsch FR, Bunn PAJ. EGFR testing in lung cancer is ready for prime time. Lancet Oncol, 2009, 10(5): 432-433.
|
7. |
凌云, 邱田, 李卓, 等. 非小细胞肺癌中 EGFR 和 KRAS 基因突变的特点及与临床病理特征的关系. 临床与实验病理学杂志, 2015, 31(5): 536-541.
|
8. |
肖芸, 罗辉, 黄敏. 表皮生长因子受体基因突变对非小细胞肺癌临床病理与酪氨酸激酶抑制剂疗效的影响. 中国老年学杂志, 2017, 37(23): 5849-5851.
|
9. |
Kim KS, Jeong JY, Kim YC, et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res, 2005, 11(6): 2244-2251.
|
10. |
Chaft JE, Arcila ME, Paik PK, et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther, 2012, 11(2): 485-491.
|
11. |
Li H, Pan Y, Li Y, et al. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer, 2013, 79(1): 8-13.
|
12. |
Nakamura H, Saji H, Shinmyo T, et al. Association of IASLC/ATS/ERS histologic subtypes of lung adenocarcinoma with epidermal growth factor receptor mutations in 320 resected cases. Clin Lung Cancer, 2015, 16(3): 209-215.
|
13. |
Villa C, Cagle PT, Johnson M, et al. Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society. Arch Pathol Lab Med, 2014, 138(10): 1353-1357.
|
14. |
Russell PA, Wainer Z, Wright GM, et al. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol, 2011, 6(9): 1496-1504.
|
15. |
Kamiya K, Hayashi Y, Douguchi J, et al. Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma. Mod Pathol, 2008, 21(8): 992-1001.
|
16. |
Shim HS, Lee DH, Park EJ, et al. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor recetor mutations in the International Association for the Study of Lung Cancer/Amertican Thoracic Society/Eruopean Respiratory Society lung adenocarcinoma classification. Arch Pathol Lab Meb, 2011, 135(10): 1329-1334.
|
17. |
Inamura K, Ninomiya H, Ishikawa Y, et al. Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? Arch Pathol Lab Med, 2010, 134(1): 66-72.
|